- It is made available under a CC-BY 4.0 Internation
- 1 TITLE
- 2 3

Rare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: a population cohort study

Yuqi Hu, MSc<sup>1+</sup>, Le Gao, PhD<sup>1+</sup> Lingyue Zhou, MPH <sup>1</sup> Wenlong Liu, MSc<sup>1</sup> Cuiling Wei,
BEng<sup>1</sup> Boyan Liu, BSc<sup>1</sup> Qi Sun, MSc<sup>1</sup> Wenxin Tian, MPH<sup>1,4</sup> Rachel Yui Ki Chu, MPH <sup>1,3</sup> Song
Song, MSc<sup>1,4</sup> Franco Wing Tak Cheng, PhD<sup>1</sup> Joe Kwun Nam Chan, PhD<sup>3</sup> Amy Pui Pui Ng,
MD<sup>2</sup> Heidi Ka Ying Lo, MBChB<sup>3</sup> Krystal Chi Kei Lee, MBBS<sup>3</sup> Wing Chung Chang, MD<sup>3,5</sup>
William Chi Wai Wong, MD<sup>2</sup> Esther Wai Yin Chan, PhD<sup>1,4</sup> Ian Chi Kei Wong, PhD<sup>1,4,6,7</sup> Yi
Chai, PhD<sup>1,4,8</sup>\*, Francisco Tsz Tsun Lai, PhD<sup>1,2,4,6</sup>\*\*

10 AFFILIATIONS

- 11 1. Centre for Safe Medication Practice and Research, Department of Pharmacology and
- 12 Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR
- Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing
   Faculty of Medicine, The University of Hong Kong, Hong Kong SAR
- 15 3. Department of Psychiatry, School of Clinical Medicine, Li Ka Shing Faculty of Medicine,
- 16 The University of Hong Kong, Hong Kong SAR
- 4. Laboratory of Data Discovery for Health (D<sup>2</sup>4H), Hong Kong Science Park, Sha Tin, Hong
  Kong SAR
- 19 5. State Key Laboratory of Brain & Cognitive Sciences, the University of Hong Kong, Hong20 Kong SAR
- 21 6. Advanced Data Analytics for Medical Science (ADAMS) Limited, Hong Kong SAR
- 22 7. Aston Pharmacy School, Aston University Birmingham, United Kingdom
- 23 8. The Hong Kong Jockey Club Centre for Suicide Research and Prevention, The University of
- 24 Hong Kong, Hong Kong SAR
- 25 + Contributed equally as first authors
- 26 ✤ Joint senior authors
- 27 \* Corresponding author. Postal address: L2-26A, Laboratory Block, Li Ka Shing Faculty of
- 28 Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong SAR; Email:
- 29 <u>fttlai@hku.hk;</u> Phone: +852 3910-3836

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 30 ABSTRACT

31 Background:

Recent disproportionality analyses and nationwide case-control studies suggested a potential
 association between clozapine use and hematological malignancy (HM). Nevertheless, the
 absolute rate difference is unclear due to the absence of cohort studies.

35 Methods:

We extracted data from a territory-wide public healthcare database in Hong Kong to build a retrospective cohort of anonymized patients aged 18+ with a diagnosis of schizophrenia who used clozapine or olanzapine (drug comparator with highly similar chemical structure and pharmacological mechanisms) for 90+ days, with at least two prior other antipsychotic use records within both groups. Weighted by inverse probability of treatment based on propensity scores, Poisson regression was used to estimate the incidence rate ratio (IRR) of HM between

- 42 clozapine and olanzapine users. The absolute rate difference was also estimated.
- 43 Results:

44 In total, 9,965 patients were included, with 834 clozapine users, who had a significant IRR of

45 2.22 (95% CI 1.52, 3.34) for HM compared to olanzapine users. Absolute rate difference was

46 estimated to be 57.40 (95% CI 33.24, 81.55) per 100,000 person-years. Findings were

47 consistent across sub-groups by age and sex in terms of effect size, although the IRR was non-

48 significant for those aged 65 or older. Sensitivity analyses all supported the robustness of the

49 results and showed good specificity to HM but no other cancers.

50 Conclusion:

51 Absolute rate difference in HM incidence was very small although there is a twofold elevated

- 52 rate. Pharmacotherapies with clozapine may consider this potential rare risk in addition to
  - 53 known side effects.
- 54
- 55 KEYWORDS

56 Cancer epidemiology; haematology; oncology; psychopharmacology; real-world evidence;

- 57 treatment-resistant schizophrenia
- 58

#### 59 **INTRODUCTION**

The rare vet elevated incidence of cancer associated with antipsychotic use, particularly breast 60 cancer, has been noted in previous research.<sup>1-3</sup> However, randomized controlled trials 61 investigating these relatively rare long-term safety outcomes are oftentimes infeasible. Of note, 62 63 real-world evidence on the risk of hematological malignancy (HM) associated with the use of clozapine, an atypical antipsychotic agent, is accruing. A disproportionality analysis of 64 VigiBase® in 2020 initially provided preliminary analytical evidence on such an association 65 66 for clozapine.<sup>4</sup> This finding underscores the need for further pharmacovigilance actions.<sup>5</sup> 67 Previous research has shown that clozapine is associated with hematological abnormalities, such as agranulocytosis, eosinophilia and thrombocytopenia.<sup>6</sup> In 2022, a nationwide Finnish 68 69 study used a population-based case-control design and suggested a threefold increase in the 70 odds of HM after using clozapine compared to other antipsychotics.<sup>7</sup> Similarly, a recent case-71 control study using the United States Veteran Health Administration Database showed 72 comparable results.<sup>8</sup> Due to their retrospective ascertainment of antipsychotic use, however, 73 the comparison between specific antipsychotic agents is not without limitations. Though there 74 was also a cohort study design in the Finnish study, it was used to estimate the crude incidence 75 rate of HM without multivariable analyses. The absolute rate difference, e.g., number of HM 76 cases associated with clozapine use per 100,000 person years, remains to be estimated.

Moreover, clozapine is typically initiated at a different level of drug resistance in patients 77 compared to most other antipsychotics.9 In fact, it is the only drug approved by the U.S. Food 78 79 and Drug Administration for treatment-resistant schizophrenia.<sup>10</sup> Hence, before using 80 clozapine, patients have likely used other antipsychotics, and indication bias or confounding 81 by other drugs is highly plausible. Unfortunately, the comparison between clozapine and other 82 drugs on a comparable timeframe was not feasible in the retrospective case-control approach 83 to the ascertainment of drug use. In light of this potential bias, an analytic cohort study that takes into consideration previous drug use as a proxy for the level of drug resistance is needed 84 to substantiate the findings. Of equal importance, a cohort study can provide an estimate of the 85 potential absolute rate difference to better inform clinical decisions. 86

87 In this study, we took advantage of a territory-wide public healthcare database in Hong Kong with comprehensive linkage to various healthcare attendance records, diagnoses and 88 medication use among people with schizophrenia. We aimed to test for the association of 89 90 clozapine use with HM in comparison with olanzapine users, adjusting for prior other antipsychotic use within both groups. Olanzapine was chosen as a comparator due to its similar 91 92 chemical structure and increasing advocacy in recent years for it to serve as an alternative to 93 clozapine for treatment-resistant schizophrenia.<sup>11,12</sup> We hypothesize an elevated risk of HM following the use of clozapine compared with olanzapine. 94

95

#### 96 **METHODS**

97 Data source

98 We adopted a retrospective cohort study design for this study. The Hospital Authority of Hong 99 Kong, which is the sole provider of public inpatient services and a major provider of public outpatient services, provided strictly anonymized and de-identified electronic health records 100 for data analysis. As all legal residents of Hong Kong are eligible for receiving services from 101 the public sector, the database essentially covers the entire population and all territories of 102

103 Hong Kong. The electronic health records were extracted from the Clinical Management 104 System in which clinicians input routine patient attendance, diagnosis and medication records daily, linked by a unique person identity number. Diagnoses are coded based on the 105 106 International Classification of Diseases, Ninth Revision, Clinical Modifications (ICD-9-CM), 107 while medications are coded with British National Formulary codes as well as generic names, with dosage and duration information also available. Timestamps are available for every record 108 109 entry, facilitating the delineation of the temporality of records and events. Many pharmacoepidemiologic research studies have already been published using this database,<sup>13-16</sup> 110 111 with the accuracy of diagnostic codes well established.<sup>17</sup>

112 *Participants* 

We included anonymized patients aged 18 years or older with a diagnosis of schizophrenia 113 114 (ICD-9-CM code 295) and a record of using clozapine or olanzapine for a duration of 90 days or more in January 2001 - August 2022. The first prescription of clozapine or olanzapine date 115 was designated as the index date. Patients who i.) did not use at least two other antipsychotics 116 117 before the index date, ii.) those who ever used both clozapine and olanzapine in their prescription history, and iii.) those who had a prior record of any cancers(including HM) before 118 the index date were excluded. Records dating back to the year 1999 were used to execute these 119 120 exclusion criteria. Patients were followed from the index date (i.e., 90 days or more clozapine or olanzapine use) until i.) the diagnosis of HM, ii.) death, iii.) five years after the cessation of 121 122 olanzapine or clozapine use, or iv.) end of data availability (i.e., August 31st 2022), whichever 123 came earliest.

124 Ethics approval for this study was obtained from the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB, 125 126 reference number: UW 20-113). Informed consent was waived as a requirement for ethics 127 approval because the data were all anonymized.

128 **Outcomes** 

Any HM diagnosis (ICD-9-CM codes 200-209, 238.4, 238.5, 238.6, 238.7, detail in eTable 1) 129 as a composite measure was adopted as the outcome of this study. 130

*Exposure and comparator* 131

Clozapine and olanzapine were identified by their generic names in the electronic health 132 records. We did not consider a 7-day, or a shorter, gap between repeated prescriptions of 133 134 antipsychotics as a discontinuation given a half-life of olanzapine ranging from 21 to 54 hours.<sup>18</sup> Clozapine was the primary exposure in this study while olanzapine was the comparator. 135

136 Statistical analysis

Poisson regression was used to estimate the incidence rate ratio (IRR) with 95% confidence 137 intervals (CI) of HM between clozapine and olanzapine users, with an offset term to account 138 for varying follow-up times for each patient. The inverse probability of treatment weighting 139 140 (IPTW), using a propensity score, was applied to balance the characteristics between the 141 clozapine and olanzapine users. The score was estimated by the logistics regression, 142 considering covariates including age, sex, previous use of categories of antipsychotics 143 according to their chemical structure (phenothiazines, thioxanthene derivatives. 144 diphenylbutylpiperidine derivatives, butyrophenone derivatives, benzamides. indole

145 derivatives, diazepines, oxazepines, thiazepines and oxepines, and other antipsychotics), prior 146 mental disorder diagnoses (depression, bipolar disorder, and dementia), number of antipsychotic used in the past year, and immunological disease history (autoimmune disease 147 148 and acquired immune deficiencies) which have been proven to associate with the HM also used as covariates<sup>19,20</sup>. eTable 1 shows the ICD-9-CM codes and generic drug names used to 149 ascertain the covariates. The standardized mean difference (SMD) was used to identify 150 151 potential imbalances between clozapine and olanzapine users. Covariates with an SMD greater than 0.1 after IPTW were further adjusted in the regression model. In addition to IRRs, 152 153 weighted absolute rate differences were also estimated between the two groups.

154 Subgroup analyses by age group and sex were conducted to provide specific estimates for 155 different demographic strata. Additionally, several sensitivity analyses were conducted to test the robustness of our results: i) the cohort was further restricted to patients using clozapine or 156 157 olanzapine for 180 days (instead of 90); ii) patients were censored for three years (instead of 158 five) after their cessation of clozapine or olanzapine use; iii) a multivariable Poisson regression 159 to employed to replicate the analysis; iv) a Cox regression with the IPTW approach was used 160 to estimate the hazard ratio; and v) asthma (ICD-9-CM codes 493) and other cancers (ICD-9-161 CM codes 140-239, excluding HM) were used as negative control outcomes to check for any unmeasurable selection bias, as it shared the same potential source of bias with HM but was 162 not causally related to antipsychotic exposure. 163

- YH and LG were independent analysts of this study to minimize errors in coding and 164 165 programming.
- 166
- 167 RESULTS

We identified 444,716 people from the database who had a prescription of antipsychotics 168 between January 2001 and August 2022. After applying the exclusion criteria, the cohort size 169

- was 9,965, comprising 834 clozapine users and 9,131 olanzapine users. Figure 1 shows the 170
- flowchart of the cohort selection procedure. 171
- 172 Cohort characteristics

**Table 1** shows the baseline characteristics of the cohort before and after applying IPTW. 173 Before weighting, the mean age of the clozapine group  $(41.00 \pm 15.02)$  was approximately five 174 years younger than that of the olanzapine group. The olanzapine group had a higher proportion 175 176 of men (54.0%) than women, while clozapine the group had a smaller proportion of men 177 (46.6%). On average, the follow-up time of the clozapine users were 4540.90 days compared to 2664.43 days follow-up time in olanzapine users, and more clozapine users prescribed more 178 179 than three kinds of other antipsychotics in the past year (59.5% versus 36.9%). Notable differences were observed in the types of previous antipsychotics use. Specifically, 180 181 phenothiazines (82.6% versus 64.6%) and thioxanthene derivatives (52.8% versus 37.4%) were more often used previously among clozapine users than olanzapine users. However, more 182 olanzapine users had used diazepines, oxazepines, thiazepines, and oxepines (39.5% versus 183 184 28.4%), and 'other antipsychotics' (71.9% versus 57.3%). Additionally, a higher prevalence of psychiatric comorbidities and immunological diseases was observed among olanzapine users. 185 186 After weighting, the SMD of characteristics were all less than 0.1 except prior benzamide use, 187 which was adjusted in the subsequent weighted regression analysis.

# 188 Main analysis

189 Figure 2 shows the weighted cumulative incidence curves of HM over the follow-up period 190 for clozapine and olanzapine users. The incidence of HM among clozapine users was 191 consistently higher than that among olanzapine users for nearly the entire follow-up period.

Among all 9,965 individuals exposed to olanzapine or clozapine, a total of 39 individuals were diagnosed with HM. Out of the 39 cases, nine individuals were clozapine users (n = 834), while the remaining 30 individuals were olanzapine users (n = 9,131). Six clozapine users and 23 in olanzapine users developed HM after discontinuing the medication. For the six clozapine users, the average number of days between their discontinuation and HM was 256.67 days. For the

197 23 olanzapine users, the number was 713.86 days.

198 Results from the Poisson regression models show that compared to olanzapine users, clozapine 199 users had a significantly higher IRR of 2.22 (95% CI 1.52, 3.34) for HM (**Table 2**). The 200 absolute rate difference of HM between the two groups was 57.40 (95% CI 33.24, 81.55) per 100,000 person-years.

Subgroup analyses showed a significantly elevated risk of HM among clozapine users for all
 sex and age groups, except for those aged 65 or older despite a comparable IRR.

204 *Sensitivity analysis* 

Sensitivity analyses yielded similar results (eTable 2). The IRR for asthma as a negative
control outcome was not significant and close to one (IRR 0.90, 95% CI 0.66,1.21). Likewise,
the IRR for other cancers was estimated at 0.77 (95% CI 0.68, 0.86).

- 208
- 209 DISCUSSION

Findings from this territory-wide cohort study involving approximately 10,000 individuals 210 with schizophrenia in Hong Kong suggested a rare but twofold increased rate of HM associated 211 212 with clozapine compared to olanzapine. Nevertheless, the absolute rate difference is small, with less than 60 additional cases of HM per 100,000 person years of clozapine use compared with 213 olanzapine use. Potential confounding factors, such as previous other antipsychotic use, 214 215 underlying mental illnesses, and history of immunological diseases observed at the baseline, 216 were properly adjusted. Subgroup analyses by age and sex, as well as sensitivity analyses, showed highly robust results, supporting a comparably strong and highly specific association. 217 218 Our research hypothesis is therefore well supported by the data.

## 219 *Relationship with the literature*

220 To the best of our knowledge, this work is the world's first analytic cohort study on this association to estimate absolute rate differences, with only two prior notable case-control 221 studies conducted in Finland<sup>7</sup> and the United States.<sup>8</sup> Although the Finnish study also provided 222 223 descriptive data on the incidence of HM using a cohort design, no hypothesis testing was 224 conducted in the cohort study. Indeed, our descriptive absolute risk estimates were highly comparable with the Finnish study's descriptive cohort.<sup>7</sup> The rarity of HM and the relatively 225 low prevalence of clozapine use compared to some other widely used antipsychotics have both 226 greatly limited previous research on this association, despite compelling evidence on the 227 association between clozapine use and a range of hematological abnormalities.<sup>21-23</sup> In fact, 228

229 apart from this and the two case-control studies, existing evidence on an association with HM 230 arose only from passive reporting systems using disproportionality analysis which may be subject to more biases than large electronic health record epidemiologic studies due to known 231 limitations in adverse event reporting platforms and databases.<sup>5,24</sup> The previous case-control 232 233 studies, despite the strengths of the national registry and comprehensive veteran health database, 234 used retrospectively ascertained long-term clozapine use as the main exposure and 'little to no 235 such use' as the comparator. This approach is not without limitations, as clozapine use is most typically preceded by a range of other antipsychotic use in the individuals because it is widely 236 regarded as the most efficacious drug available.<sup>25</sup> Our current study address this challenge by 237 238 confining our cohort to those who used two other antipsychotics before using clozapine (or 239 olanzapine) and employing olanzapine as an active comparator.<sup>26</sup> This ensures a more proper 240 adjustment of previous antipsychotic use before clozapine or olanzapine initiation. With a 241 cohort design, we also estimated the absolute rate difference which is highly relevant in clinical 242 decision making. The current study represented evidence that is one level higher up the clinical 243 evidence pyramid compared with the existing knowledge, i.e., from case-control to cohort 244 evidence.

#### 245 Interpretation of observed association

The strong association observed in this and the previous two case-control studies<sup>7</sup> as well as its 246 good coherence with previous evidence on the hematological abnormalities<sup>27</sup> associated with 247 clozapine constitute a strong case that this association is likely causal. We believe the effects 248 249 of such abnormalities being induced by the prolonged use of clozapine may accumulate over 250 the duration of use and potentially increase the risk of malignancy through a range of potential mechanisms.<sup>28</sup> For instance, recent evidence showed that the elevated risk of agranulocytosis 251 252 following clozapine use may persist well over several years, and this mechanism could 253 potentially impact the increased risk of other blood-related disorders among clozapine users. 254 including a higher risk of HM.<sup>29</sup> We did not have a sufficient number of cases to separately 255 analyze the type of HM with a more significantly elevated risk; inference about the specific 256 underlying mechanism is thus limited. Further research should investigate specific HM types.

### 257 Potential clinical implications

Despite a small rate difference, a potential strong association between clozapine use and HM, 258 if substantiated by further evidence, would provide additional information to the safety profile 259 of the drug compared to olanzapine. This potential slight recalibration of the risk-benefit 260 balance may partially impact clinical decisions about long-term clozapine use. First, 261 considering the markedly elevated risk of HM, despite its rare incidence, psychiatrists may be 262 263 more inclined to try other antipsychotics before initiating clozapine, which is currently the most efficacious antipsychotic drug. Second, for individuals with significant hematological 264 abnormalities detected early in the course of clozapine use, alternative drugs may be beneficial, 265 266 as prolonged use of clozapine may be associated with a higher chance of HM. Third, patients with a family history of HM may benefit from reconsideration of clozapine prescription, as 267 they have a higher baseline risk.<sup>30</sup> These potential considerations need to be supported by 268 additional evidence, such as studies specific to individuals with a family history of HM and the 269 270 relationship between detected hematological abnormalities and subsequent HM risks.

#### 271 Strengths and limitations

One of the key strengths of this study is the cohort design with a range of important covariates 272 273 properly adjusted, e.g., prior antipsychotic use, providing highly useful information on the

274 absolute rate of HM and the rate difference. Additionally, the territory-wide database with 275 comprehensive medical records based on the same coding system and practices also confers great strengths, such as good generalizability and representativeness of the findings. 276

277 There are, nevertheless, limitations that warrant caution. First, this evidence is observational 278 without randomization, which may entail potential selection or indication bias. Nevertheless, blood tests prior to the prescription of clozapine should have already excluded people with a 279 280 higher risk of HM; such indication bias, if any, might lead to an underestimation of the observed 281 association. Moreover, it is difficult to conduct randomized prospective studies on such a rare 282 outcome, so future research should likely still be focused on observational studies with multiple sites or even countries. Second, although olanzapine, particularly in high doses, can be useful 283 284 for some cases, it is not a suggested replacement option for clozapine in the treatmentresistance schizophrenia due to the lack of a highly comparable indication.<sup>31</sup> Third, there are 285 286 unobserved covariates such as socioeconomic status and lifestyle factors that were not included 287 in this study. Fourth, there may be a detection bias of HM for clozapine, as it is known to be 288 associated with hematological abnormalities which are closely monitored.<sup>32</sup> However, since 289 we allowed the observation to last until five years after discontinuation to account for 290 symptomatic presentation, the detection bias should not be significant. Also, the association is 291 strong and unlikely to be purely arising from detection bias, i.e., earlier detection. In fact, our findings showed that a smaller proportion of HM cases was recorded during the use of 292 293 clozapine than that during the use of olanzapine. Fifth, the dosage of treatment was not 294 standardized during the course of treatment or across individuals and is subject to the 295 psychiatrists' clinical judgement for each individual. Sixth, the follow-up time for the olanzapine group was shorter than that of the clozapine group, but it should likely be long 296 297 enough to observe and capture the study outcome, with a mean follow-up time of more than 298 seven years. Seventh, among clozapine users, many had used olanzapine before switching to 299 clozapine in clinical practice but we excluded approximately 5,000 patients who had a history 300 of using olanzapine either before or after starting clozapine treatment. This exclusion has 301 limited our sample size although we arrived at a more selective sample for a fair comparison. 302 Finally, the study population in Hong Kong is predominantly ethnic Chinese, and the 303 generalizability of the findings to other populations need to be tested using multinational data.

### 304 **CONCLUSIONS**

To conclude, we conducted a territory-wide retrospective cohort study in Hong Kong and 305 identified a rare but evidently elevated risk of HM, i.e., twofold, among clozapine users with 306 307 schizophrenia compared with olanzapine users. If substantiated by further studies, the risk-308

benefit ratio of the long-term prescription of clozapine should be slightly recalibrated.

## 309 FUNDING

No specific funding was received for this project. FTTL and ICKW are partially supported by
the Laboratory of Data Discovery for Health (D24H) funded by the by AIR@InnoHK
administered by the Innovation and Technology Commission.

# 313 CONTRIBUTORS' STATEMENT

314 Yuqi Hu, Le Gao, Yi Chai and Francisco Lai contributed to the conception of the work. All authors designed the study. Yuqi Hu and Le Gao contributed to the acquisition and analysis of 315 the data, and all authors interpreted the data. Yuqi Hu and Francisco Lai drafted the manuscript. 316 317 All authors revised the manuscript critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work. 318 319 Yuqi Hu and Le Gao are co-first authors. Yi Chai and Francisco Lai share the senior authorship, 320 had full access to all the data in the study and took final responsibility for the decision to submit for publication. 321

- **322** COMPETING INTERESTS
- None declared.
- 324 ACKNOWLEDGEMENTS

The authors thank the Hospital Authority for the generous provision of data and gratefully acknowledge Professor Martin Roland of the University of Cambridge for his invaluable advice.

## 327 DATA AVAILABILITY

The data underlying the results presented in the study are available from Hong Kong Hospital
Authority's Central Panel on Administrative Assessment of External Data Requests
(https://www3.ha.org.hk/data/Provision/Submission).

331

## **332** REFERENCES

- Leung JCN, Ng DWY, Chu RYK, et al. Association of antipsychotic use with breast cancer: a systematic review and meta-analysis of observational studies with over 2 million individuals. *Epidemiol Psychiatr Sci.* Sep 5 2022;31:e61. doi:10.1017/s2045796022000476
- 337 Chu RYK, Wei Y, Osborn DP, et al. Breast cancer risks following antipsychotic use in 2 338 women with bipolar disorder versus schizophrenia: A territory-wide nested case-control 339 study spanning two decades. Psychiatry Res. Aug 2023;326:115287. 340 doi:10.1016/j.psychres.2023.115287
- Taipale H, Solmi M, Lähteenvuo M, Tanskanen A, Correll CU, Tiihonen J. Antipsychotic
   use and risk of breast cancer in women with schizophrenia: a nationwide nested case control study in Finland. *Lancet Psychiatry*. Oct 2021;8(10):883-891. doi:10.1016/s2215 0366(21)00241-8
- 345 4. Chrétien B, Lelong-Boulouard V, Chantepie S, et al. Haematologic malignancies
  346 associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in
  347 VigiBase(®). *Psychol Med.* Jul 2021;51(9):1459-1466. doi:10.1017/s0033291720000161
- 348 5. de Leon J, De Las Cuevas C, Sanz EJ, Verdoux H. The association of clozapine and hematological malignancies needs to be replicated by other studies and more importantly by analyses of subsamples from VigiBase. *Psychol Med.* Jun 2021;51(8):1405-1406. doi:10.1017/s0033291720001233
- Grover S, Shouan A, Chakrabarti S, Avasthi A. Hematological side effects associated with
   clozapine: A retrospective study from India. *Asian Journal of Psychiatry*. 2020/02/01/
   2020;48:101906. doi:https://doi.org/10.1016/j.ajp.2019.101906
- Tiihonen J, Tanskanen A, Bell JS, Dawson JL, Kataja V, Taipale H. Long-term treatment
  with clozapine and other antipsychotic drugs and the risk of hematological malignancies
  in people with schizophrenia: a nationwide case-control and cohort study in Finland. *Lancet Psychiatry*. May 2022;9(5):353-362. doi:10.1016/s2215-0366(22)00044-x
- Brainerd DR, Alexander B, Tague MJ, Lund BC. Association Between Clozapine
   Exposure and Risk of Hematologic Malignancies in Veterans With Schizophrenia. *Journal of Clinical Psychiatry*. 2024;85(2):23m15149.
- 362 9. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant
  363 schizophrenic. A double-blind comparison with chlorpromazine. *Arch Gen Psychiatry*.
  364 Sep 1988;45(9):789-96. doi:10.1001/archpsyc.1988.01800330013001
- 365 10. Fenton C, Kang C. Clozapine is the approved option in treatment-resistant schizophrenia
  and requires careful management. *Drugs Ther Perspect*. 2023;39(3):107-113.
  doi:10.1007/s40267-023-00982-6
- 368 11. Souza JS, Kayo M, Tassell I, Martins CB, Elkis H. Efficacy of olanzapine in comparison
  369 with clozapine for treatment-resistant schizophrenia: evidence from a systematic review
  370 and meta-analyses. *CNS Spectr.* Apr 2013;18(2):82-9. doi:10.1017/s1092852912000806
- 371 12. Gannon L, Reynolds J, Mahon M, Gaughran F, Lally J. High-dose olanzapine in treatment-resistant schizophrenia: a systematic review. *Ther Adv Psychopharmacol*. 2023;13:20451253231168788. doi:10.1177/20451253231168788
- 13. Lai FTT, Li X, Peng K, et al. Carditis After COVID-19 Vaccination With a Messenger
  RNA Vaccine and an Inactivated Virus Vaccine : A Case-Control Study. *Ann Intern Med.*Mar 2022;175(3):362-370. doi:10.7326/m21-3700
- Huang C, Wei Y, Yan VKC, et al. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study. *Lancet Psychiatry*. Jun 2023;10(6):403-413. doi:10.1016/s2215-0366(23)00111-6


- 381 15. Lau WC, Chan EW, Cheung CL, et al. Association Between Dabigatran vs Warfarin and 382 Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation. Jama. Mar 21 2017;317(11):1151-1158. doi:10.1001/jama.2017.1363 383
- 384 16. Man KKC, Chan EW, Ip P, et al. Prenatal antidepressant use and risk of attention-385 deficit/hyperactivity disorder in offspring: population based cohort study. Bmj. May 31 386 2017;357:j2350. doi:10.1136/bmj.j2350
- 387 17. Wong AY, Root A, Douglas IJ, et al. Cardiovascular outcomes associated with use of 388 clarithromycin: population based study. Bmj. Jan 14 2016;352:h6926. 389 doi:10.1136/bmj.h6926
- 390 18. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Clinical 391 Pharmacokinetics. 1999/09/01 1999;37(3):177-193. doi:10.2165/00003088-199937030-392 00001
- 393 19. Hemminki K, Huang W, Sundquist J, Sundquist K, Ji J. Autoimmune diseases and 394 hematological malignancies: Exploring the underlying mechanisms from epidemiological 395 evidence. Seminars in Cancer Biology. 2020/08/01/ 2020;64:114-121. doi:https://doi.org/10.1016/j.semcancer.2019.06.005 396
- 397 20. Kimani SM, Painschab MS, Horner M-J, Muchengeti M, Fedoriw Y, Shiels MS, Gopal S. 398 Epidemiology of hematological malignancies in people living with HIV. The Lancet HIV. 399 2020;7(9):e641-e651.
- 400 21. Myles N, Myles H, Xia S, et al. Meta-analysis examining the epidemiology of clozapine-401 associated neutropenia. Acta Psychiatrica Scandinavica. 2018;138(2):101-109. 402 doi:https://doi.org/10.1111/acps.12898
- 403 22. Myles N, Myles H, Xia S, et al. A meta-analysis of controlled studies comparing the 404 association between clozapine and other antipsychotic medications and the development 405 of neutropenia. Australian & New Zealand Journal of Psychiatry. 2019;53(5):403-412. 406 doi:10.1177/0004867419833166
- 23. Ratanajamit C, Musakopas C, Vasiknanonte S, Reanmongkol W. Incidence and risk for 407 408 neutropenia/agranulocytosis among clozapine users: A retrospective cohort study. 409 International Journal of Psychiatry in Clinical Practice. 2010/01/01 2010;14(2):109-115. doi:10.3109/13651500903402450 410
- 24. Dawson JL, Sluggett JK, Procter NG, Myles N, Bell JS. Hematological and Other Cancers 411 in People Using Clozapine: Analysis of Australian Spontaneous Reports Between 1995 412 413 2020. Journal of Clinical *Psychopharmacology*. and 2023:43(4):333-338. doi:10.1097/jcp.000000000001699 414
- 25. Correll CU, Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Seppälä N, Howes 415 416 OD. A Guideline and Checklist for Initiating and Managing Clozapine Treatment in 2022/07/01 417 Treatment-Resistant Schizophrenia. CNS Drugs. Patients with 418 2022;36(7):659-679. doi:10.1007/s40263-022-00932-2
- 419 26. Wintzell V, Svanström H, Pasternak B. Selection of Comparator Group in Observational Drug Safety Studies: Alternatives to the Active Comparator New User Design. 420 *Epidemiology*. 2022;33(5):707-714. doi:10.1097/ede.00000000001521 421
- 27. Blackman G, Lisshammar JEL, Zafar R, et al. Clozapine Response in Schizophrenia and 422 423 Hematological Changes. Journal of Clinical Psychopharmacology. 2021;41(1):19-24. doi:10.1097/jcp.00000000001329 424
- 28. Nooijen PMM, Carvalho F, Flanagan RJ. Hematological toxicity of clozapine and some 425 426 other drugs used in psychiatry. Human Psychopharmacology: Clinical and Experimental. 2011/03/01 2011;26(2):112-119. doi:https://doi.org/10.1002/hup.1181 427
- 428 29. Rubio JM, Kane JM, Tanskanen A, Tiihonen J, Taipale H. Long-term persistence of the 429 risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide

- 430 cohort and case–control study in Finland. The Lancet Psychiatry. 431 doi:10.1016/S2215-0366(24)00097-X
- 30. Clemmensen SB, Harris JR, Mengel-From J, Bonat WH, Frederiksen H, Kaprio J, 432 Hjelmborg JvB. Familial Risk and Heritability of Hematologic Malignancies in the Nordic 433 Twin Study of Cancer. Cancers. 2021;13(12):3023. 434
- 31. Gannon L, Reynolds J, Mahon M, Gaughran F, Lally J. High-dose olanzapine in 435 436 treatment-resistant schizophrenia: a systematic review. Therapeutic Advances in Psychopharmacology. 2023;13:20451253231168788. 437
- 32. Smessaert S, Detraux J, Desplenter F, De Hert M. Evaluating Monitoring Guidelines of 438 439 Clozapine-Induced Adverse Effects: a Systematic Review. CNS Drugs. 2024/02/01 2024;38(2):105-123. doi:10.1007/s40263-023-01054-z 440
- 33. Khokhar JY, Henricks AM, Sullivan ED, Green AI. Unique effects of clozapine: a 441 442 pharmacological perspective. Advances in pharmacology. 2018;82:137-162.

444 Figure 1. Flow chart showing cohort selection processes.




Patients who have ever used antipsychotics between January 2001 - August 2022 (n = 444,786)



446

#### 447 Figure 2. Cumulative incidence curves over the observation period by clozapine or olanzapine use status. Yellow represents clozapine and blue represents olanzapine. 448



449

450 451

Strata - Clozapine - Olanzapine

# Table 1. Cohort characteristics

		Unweighted	Weighted by inverse probability of treatment			
	Olanzapine	Clozapine	SMD <sup>a</sup>	Olanzapine	Clozapine	SMD a
Ν	9131	834		9964.8	10101.1	
Mean age (standard deviation)	46.48 (15.0)	41 (11.5)	0.404	46.0 (14.9)	44.8 (12.9)	0.084
Sex (%)			0.144			0.036
Men	4932 (54)	389 (46.6)		4643 (46.6)	4541 (45)	
Women	4199 (46)	445 (53.4)		5321 (53.4)	5560 (55)	
Number of other antipsychotic drugs used in the past year			0.515			0.024
0	215 (2.4)	22(2.6)		237 (2.4)	245 (2.4)	
1	2203 (24.1)	81(9.7)		2284 (22.9)	2229 (22.1)	
2	3348 (36.7)	235(28.2)		3583 (36.0)	3724 (36.9)	
≥3	3365 (36.9)	469(59.5)		3861 (38.7)	3903 (38.6)	
Previous other antipsychotics use (%)						
Phenothiazines	5902 (64.6)	689 (82.6)	0.413	6591 (66.1)	6493 (64.3)	0.043
Thioxanthene derivatives	3413 (37.4)	440 (52.8)	0.316	3853 (38.7)	3638 (36)	0.057
Diphenylbutylpiperidine derivatives	222 (2.4)	44 (5.3)	0.150	265 (2.7)	288 (2.8)	0.011
Butyrophenone derivatives	6532 (71.5)	621 (74.5)	0.069	7155 (71.8)	7245 (71.7)	0.001
Benzamides	3949 (43.2)	364 (43.6)	0.013	4320 (43.4)	4903 (48.5)	0.103
Indole derivatives	536 (5.9)	65 (7.8)	0.076	602 (6.0)	753 (7.5)	0.057
Diazepines, oxazepines, thiazepines and oxepines	3605 (39.5)	237 (28.4)	0.232	3843 (38.6)	4239 (42)	0.071
Other antipsychotics	6563 (71.9)	478 (57.3)	0.312	7043 (70.7)	7400 (73.3)	0.059
Mental illness diagnoses (%)		~ /		~ /		
Depression	1132 (12.4)	61 (7.3)	0.170	1194 (12.0)	1283 (12.7)	0.048
Bipolar disorder	1118 (12.2)	73 (8.8)	0.118	1192 (12.0)	1362 (13.5)	0.006
Dementia	154 (1.7)	2 (0.2)	0.148	156 (1.6)	165 (1.6)	0.050
History of immunological diseases (%)	248 (2.7)	18 (2.2)	0.032	265 (2.7)	191 (1.9)	0.028

<sup>a</sup> Standardized mean difference

				Crude	Weighted			
		Average		incidence	incidence			
		follow-up	Number	rate of HM	rate of HM			Weighted absolute rate
	Cohort	duration	of HM	per 100,000	per 100,000			difference per 100,000
	size	(days)	cases	person-year	person-year	Crude IRR (CI)	Weighted IRR (CI)	person-years (CI)
Main analysis	9,965	2821.47	39	50.66	78.01			57.40 (33.24,81.55)
Olanzapine	9,131	2664.43	30	45.04	43.75	Ref.	Ref.	
Clozapine	834	4540.90	9	86.80	101.15	1.93 (0.86,3.90)	2.22 (1.52,3.34)	
Men	4,644	2763.26	18	51.23	76.01			46.04 (9.57,82.52)
Olanzapine	4,199	2581.79	15	50.54	48.98	Ref.	Ref.	
Clozapine	445	4475.57	3	55.02	95.02	1.09 (0.25,3.30)	2.33 (1.33,4.31)	
Women	5,321	2872.28	21	50.19	72.26			54.27 (23.41,85.14)
Olanzapine	4,932	2734.78	15	40.62	39.34	Ref.	Ref.	
Clozapine	389	4615.64	6	122.06	93.61	3.00 (1.07,7.39)	2.35 (1.38,4.24)	
Aged 44 or younger	4,821	3196.96	8	18.96	27.93		\$ · · ·	23.49 (4.33,42.64)
Olanzapine	4,301	2980.84	5	14.24	13.75	Ref.	Ref.	
Clozapine	520	4984.57	3	42.27	37.24	2.97 (0.61,12.10)	2.71 (1.15,7.67)	
Aged 45 - 64	3,967	2620.41	22	77.30	110.06	· · · · ·	, <u>,</u> , ,	72.69 (25.06,120.31)
Olanzapine	3,674	2518.13	17	67.12	66.96	Ref.	Ref.	
Clozapine	293	3902.97	5	159.7	139.65	2.38 (0.78,6.01)	2.07 (1.24,3.65)	
Aged 65 or older	1,177	1961.14	9	142.41	192.19	· · · · · · · · · · · · · · · · · · ·		137.22 (0.00,301.95)
Olanzapine	1,156	1952.16	8	129.48	129.34	Ref.	Ref.	
Clozapine	21	2455.48	1	708.33	266.55	5.47 (0.29,29.81)	1.90 (0.62,5.78)	

Table 2. Incidence rate ratios (IRR) of hematological malignancy (HM) with 95% confidence intervals (CI)

Disease name/ Drug category	ICD-9-CM codes/ drug names
Hematological malignancy	
Lymphosarcoma and reticulosarcoma	200
Hodgkin's disease	201
Other malignant neoplasms of lymphoid and histiocytic tissue	202
Multiple myeloma and immunoproliferative neoplasms	203
Lymphoid leukaemia	204
Myeloid leukaemia	205
Monocytic leukaemia	206
Other specified leukaemia	207
Leukaemia of unspecified cell type	208
Polycythemia vera	238.4
Neoplasm of uncertain behavior of histiocytic and mast cells	238.5
Neoplasm of uncertain behavior of plasma cells	238.6
Neoplasm of uncertain behavior of other lymphatic and hematopoietic tissue	238.7
Mental illnesses	
Depression	296.2, 296.3, 300.4, 625.4, 293.83, 311, 648.4, 300.0
Bipolar disorder	296
Dementia	290, 294.1, 294.2, 294.8, 331.0, 331.1, 331.82
Immunological disease	42, 43, 44, 266.2, 273.0, 273.1, 273.2, 277.2, 277.6, 279, 288.1, 289.89
Autoimmune Diseases:	
Vitiligo	709.01
Addison disease	255.4
Alopecia areata	704.01
Autoimmune/Hashimoto's thyroiditis	245.2
Graves' disease	242
Morphoea	701
Multiple sclerosis Myasthenia gravis	340 358
Pernicious anaemia	281
Primary biliary cirrhosis	571.6
Takayasu arteritis	446.7
Type 1 diabetes mellitus	250.X1, 250.X3
Associated Conditions:	
Episcleritis/scleritis	379.0X
Erythema nodosum	695.2
Haemolytic anaemia	283.XX

eTable 1. ICD-9-CM diagnostic codes and generic drug names used to define covariates

Immune thrombocytopenia purpura	287.31
Leukocytoclastic vasculitis	446.29
Myositis	729.1
Pulmonary fibrosis/interstitial lung disease	515. X, 516.31
Raynaud's syndrome	443
Sjögren's syndrome/sicca syndrome	710.2
Thrombocytopenia purpura	287.3
Vasculitis	447.6
Juvenile idiopathic arthritis (JIA)	714.30, 714.31, 714.32, 714.33, 714.2
Acquired immune deficiencies	42, 43, 44
Asthma	493
Previous antipsychotic use	
Phenothiazines	Chlorpromazine, Perphenazine, Fluphenazine, Trifluoperazine, Pericyazine, Thioridazine
Thioxanthene derivatives	Flupenthixol, Zuclopenthixol, Thiothixene
Diphenylbutylpiperidine derivatives	Pimozide
Butyrophenone derivatives	Haloperidol, Droperidol
Benzamides	Sulpiride, Amisulpride
Indole derivatives	Lurasidone, Ziprasidone, Molindone, Sertindole
Diazepines, oxazepines, thiazepines and oxepines	Quetiapine, Asenapine
Other antipsychotics	Aripiprazole, Brexpiprazole, Risperidone, Paliperidone

	Cohort size	Average follow-up duration	Number of HM cases	Crude incidence rate of HM	Weighted incidence rate of HM	Crude IRR (HR for Cox regression)	Weighted IRR (HR for Cox regression)	Weighted absolute rate difference per 100,000 person-years (CI)
		(days)		per 100,000	per 100,000			
				person-year	person-year			
Restricting to those who used clozapine or olanzapine for 180+ days	6,091	2781.40	21	45.27	59.46			34.79 (6.94,62.65)
Olanzapine	5,529	2618.33	16	40.37	38.85	Ref.	Ref.	
Clozapine	562	4385.72	5	74.09	73.65	1.84 (0.6,4.69)	2.29 (1.29, 4.07)	
Right-censoring patients at 3 years after treatment discontinuation	9,965	2709.44	39	52.76	79.99			56.53 (31.76,81.29)
Olanzapine	9,131	2546.58	30	47.12	45.79	Ref.	Ref.	
Clozapine	834	4492.47	9	87.74	102.32	1.93 (0.86,3.91)	2.22 (1.32, 4.19)	
Multivariable Poisson regression	9,965	2821.47	39	50.66	78.01			-
Olanzapine	9,131	2664.43	30	45.04	43.75	Ref.	Ref.	
Clozapine	834	4540.90	9	86.80	101.15	1.93 (0.86,3.90)	2.53 (1.04, 5.42)	
Weighted Cox regression	9,965	2821.47	39	50.66	78.01			57.40 (33.24,81.55)
Olanzapine	9,131	2664.43	30	45.04	43.75	Ref.	Ref.	
Clozapine	834	4540.90	9	86.80	101.15	1.95 (0.91, 4.19)	2.28 (0.80, 6.48)	
Using asthma as negative control outcome	9,814	2817.21	74	97.76	106.17			8.73 (0.00, 37.93)
Olanzapine	8,989	2660.68	64	97.74	100.30	Ref.	Ref.	
Clozapine	825	4522.73	10	97.89	110.20	1.01 (0.52, 1.97)	0.90 (0.66,1.21)	
Using other cancers as negative control outcome	9,982	2747.85	597	794.98	644.99	· ·	·	175.53 (97.68, 253.3
Olanzapine	9,140	2595.88	497	765.1	749.89	Ref.	Ref.	
Clozapine	842	4397.43	70	690.52	574.35	0.90 (0.70, 1.15)	0.77 (0.68,0.86)	

eTable 2. Sensitivity analysis: incidence rate ratios (IRR) of hematological malignancy (HM) with 95% confidence intervals (CI)